HeberFERON® as a therapeutic option in basal cell carcinoma. Case report

Authors

Abstract

Introduction: skin cancer is the main cause of malignant tumors in the world. This information is relevant in the elderly, as part of all the changes experienced during aging. In Cuba, studies indicate that this type of carcinoma represents 75-80 % of diagnosed skin neoplasms, which places it within the Latin American countries with the highest incidence of non-melanotic skin cancer.

Objective: to present a patient with basal cell carcinoma located in the lower eyelid of the left eye, with possible compromise of the ocular anatomy if he underwent surgery, and for this reason he was successfully treated with HeberFERON®.

Case presentation: a 78-year-old white male patient with a history of diabetes mellitus and a history of chronic sun exposure. He came to the clinic for presenting three localized skin lesions, months of evolution, rapid growth, and easy bleeding. During the anamnesis, he stated that he had worked for many years in construction, without using sun protection. Skin biopsy of the larger lesion resulted in an ulcerated solid basal cell carcinoma, and treatment with HeberFERON® was indicated for this lesion, and excision for the minors, once its size decreased.

Conclusions: treatment with HeberFERON® constitutes a therapeutic option to avoid surgical interventions that compromise the facial anatomy. Its use is recommended in patients with basal carcinoma in locations similar to those of the patient in this study

Downloads

Download data is not yet available.

Downloads

Published

2021-10-25

How to Cite

1.
del Río Ysla MB, Abreu Rivero Y, Valle Yanes I. HeberFERON® as a therapeutic option in basal cell carcinoma. Case report. Mediciego [Internet]. 2021 Oct. 25 [cited 2026 Jan. 17];27(1):e2057. Available from: https://revmediciego.sld.cu/index.php/mediciego/article/view/2057

Issue

Vol. 27 (2021)

Section

Case Report

License

Those authors who have publications with this journal accept the following terms of the License CC Attribution-NonCommercial 4.0 International (CC BY-NC 4.0):

You are free to:

  • Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  • Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

The journal is not responsible for the opinions and concepts expressed in the works, which are the exclusive responsibility of the authors. The Editor, with the assistance of the Editorial Committee, reserves the right to suggest or request advisable or necessary modifications. Original scientific works are accepted for publication, as are the results of research of interest that have not been published or sent to another journal for the same purpose.

The mention of trademarks of specific equipment, instruments or materials is for identification purposes, and there is no promotional commitment in relation to them, neither by the authors nor by the editor.